Skip to main content
. Author manuscript; available in PMC: 2010 Apr 19.
Published in final edited form as: Histopathology. 2009 Dec;55(6):696–704. doi: 10.1111/j.1365-2559.2009.03448.x

Figure 1.

Figure 1

[A] BRCA2: In-situ and invasive prostatic carcinoma in which the in-situ components express high levels of nuclear RAD51 staining (++).

[B] BRCA1: Invasive prostatic carcinoma expressing high levels of nuclear RAD51 in the nuclei of invasive carcinoma cells. The in situ component is predominantly unstained or the cells are expressing RAD51 within the cytoplasm (+).

[C] BRCA2: Nests of poorly-differentiated prostatic carcinoma (Gleason 4+4) carcinoma expressing nuclear RAD51 (+++) in approximately 40% of nuclei.

[D] BRCA2: Poorly-differentiated (Gleason 5+5) invasive prostatic adenocarcinoma expressing RAD51 (++) within the nuclei of approximately 40% of nuclei in this field. Low levels of cytoplasmic staining are also identified.

[E] BRCA2: Nests and cords of poorly-differentiated (Gleason 5+5) prostatic carcinoma expressing high levels of RAD51 (+++) in the cytoplasm of the invasive carcinoma cells. No nuclear staining is identified.

[F] BRCA1: Cribriforming prostatic adenocarcinoma (Gleason 4+4) expressing moderate levels of RAD51 (++) within the cytoplasm of the malignant cells. No nuclear staining is evident.